| Wang, Fang |
SPH3127-301, NCT05359068: Study to Evaluate the Efficacy and Safety of SPH3127 In Patients With Mild-moderate Essential Hypertension |
|
|
| Completed | 3 | 957 | RoW | SPH3127 tablet, Valsartan | Shanghai Pharmaceuticals Holding Co., Ltd | Essential Hypertension | 12/23 | 12/23 | | |
NCT06004856: Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Chronic Primary Immune Thrombocytopenia |
|
|
| Recruiting | 3 | 195 | RoW | Orelabrutinib, Placebo | Beijing InnoCare Pharma Tech Co., Ltd. | Chronic Primary Immune Thrombocytopenia (ITP) | 12/25 | 04/26 | | |
NCT05232149: A Study to Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Immune Thrombocytopenia |
|
|
| Recruiting | 2a/2b | 30 | RoW | Orelabrutinib( lower dose), Orelabrutinib( higher dose) | Beijing InnoCare Pharma Tech Co., Ltd. | Primary Immune Thrombocytopenia | 12/23 | 12/24 | | |
| Completed | 2 | 225 | RoW | Qishen Yiqi dripping pills 2 bags/time + Qishen Yiqi dripping pills placebo 2 bags/time, Qishen Yiqi dripping pills 4 bags/time, Qishen Yiqi dripping pills placebo 4 bags/time | Tasly Pharmaceutical Group Co., Ltd | Chronic Heart Failure With Preserved Ejection Fraction | 12/24 | 12/24 | | |
NCT06606483: A Study to Evaluate the Efficacy and Safety of MDR-001 in Subjects Who Are Obesity or Overweight |
|
|
| Not yet recruiting | 2 | 300 | RoW | MDR-001, Placebo | MindRank AI Ltd | Obesity, Overweight and Obesity | 07/25 | 09/25 | | |
NCT05998759: Telitacicept for the Treatment of Connective Tissue Disease-associated Thrombocytopenia |
|
|
| Recruiting | 2 | 296 | RoW | Telitacicept, recombinant human B lymphocyte stimulating factor receptor-Fc fusion protein, Recombinant Human B Lymphocyte(RC18), Tai'ai®, Placebo, Placebo control, control | Beijing Hospital, The First Affiliated Hospital of Anhui Medical University, The First Affiliated Hospital of China University of Science and Technology (Anhui Provincial), Peking University People's Hospital, Peking University Third Hospital, First Affiliated Hospital, Sun Yat-Sen University, Guangdong Provincial People's Hospital, The First Affiliated Hospital of Zhengzhou University, Wuhan Union Hospital, China, Second Xiangya Hospital of Central South University, Xiangya Hospital of Central South University, The Affiliated Hospital of Inner Mongolia Medical University, First Hospital of China Medical University, Shandong Provincial Hospital, Changhai Hospital, RenJi Hospital, Shanxi Bethune Hospital, West China Hospital, Institute of Hematology & Blood Diseases Hospital, China, Tianjin First Central Hospital, Tianjin Medical University General Hospital, People's Hospital of Xinjiang Uygur Autonomous Region, The First People's Hospital of Yunnan | Connective Tissue Diseases, Thrombocytopenia | 12/25 | 12/25 | | |
NCT06774664: A Clinical Study of SCTC21C in Participants With Plasma Cell-driven Autoimmune Diseases |
|
|
| Not yet recruiting | 1/2 | 99 | RoW | SCTC21C | Sinocelltech Ltd. | IgA Nephropathy | 09/27 | 03/29 | | |
NCT04518696: Suprachoroidal Buckling for the Management of Rhegmatogenous Retinal Detachment |
|
|
| Not yet recruiting | N/A | 15 | NA | suprachoroidal buckling | Fang Wang | Retinal Detachment | 10/20 | 12/22 | | |
NCT05015348: Effects of Omega-3 PUFA on Lipids, Inflammatory Factors and Body Composition in Patients with Hyperlipidemia |
|
|
| Recruiting | N/A | 120 | RoW | fish oil with omega-3 PUFA, placebo | Peking Union Medical College Hospital | Hyperlipidemias | 03/24 | 12/24 | | |
NCT04520789: Early Prevention Strategies of Severe Proliferative Vitreoretinopathy Base on Precision Diagnosis of Single Cell Sequencingvitreoretinopathy |
|
|
| Not yet recruiting | N/A | 60 | NA | RPE cell collection and single cell heterogeneity study, Postoperative intervention, Conventional Surgery for Retinal Detachment | Shanghai 10th People's Hospital | Rhegmatogenous Retinal Detachment | 06/22 | 12/22 | | |
| Recruiting | N/A | 10254 | RoW | | Limeng Chen | Chronic Kidney Diseases, Chronic Kidney Disease-Mineral and Bone Disorder | 12/24 | 12/24 | | |
NCT06134973: A Prospective Study on the Application of Liquid Biopsy in the Surveillance of High-risk Population of HCC. |
|
|
| Recruiting | N/A | 1000 | RoW | ultrasonic testing | Tianjin Third Central Hospital, BGI, China | Hepatocellular Carcinoma | 06/25 | 06/25 | | |
NCT05802381: the Safety and Effectiveness of Protein Supplements on Cancer Patients With Nutritional Risk and Malnutrition |
|
|
| Not yet recruiting | N/A | 100 | NA | protein supplement, protein, nutrition counseling | Peking Union Medical College Hospital | Cancer, Malnutrition | 04/24 | 12/24 | | |
NCT05792761: A Study on Antiviral Treatment of Chronic Hepatitis B in Children |
|
|
| Recruiting | N/A | 1900 | RoW | Peginterferon alfa-2b combined and ETV | Fang Wang | Chronic HBV Infection | 12/25 | 12/25 | | |
| Wang, Fengmei |
| Active, not recruiting | 4 | 640 | RoW | Tenofovir Amibufenamide（TMF）, HS-10234 | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Hepatitis B, Chronic | 06/24 | 09/29 | | |
NCT05862337: Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence. |
|
|
| Recruiting | 3 | 480 | RoW | Anlotinib hydrochloride capsules, Penpulimab injection, Anlotinib hydrochloride capsules -matching placebo, Penpulimab injection -matching placebo | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Hepatocellular Carcinoma | 08/24 | 12/26 | | |
NATiV3, NCT04849728: A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( ) |
|
|
| Recruiting | 3 | 1000 | Europe, Canada, US, RoW | IVA337, Lanifibranor, Placebo | Inventiva Pharma | NASH - Nonalcoholic Steatohepatitis | 09/25 | 09/26 | | |
NCT04639323: Endoscopic Ruler for the Assessment of Variceal Bleeding Risks (CHESS2005) |
|
|
| Recruiting | N/A | 266 | RoW | Endoscopic ruler | Hepatopancreatobiliary Surgery Institute of Gansu Province, LanZhou University, Tianjin Second People's Hospital, The First Affiliated Hospital with Nanjing Medical University, People's Hospital of Ningxia Hui Autonomous Region, The Second Affiliated Hospital of Baotou Medical College, The Third Xiangya Hospital of Central South University, The Second Hospital of Hebei Medical University, The Affiliated Hospital Of Southwest Medical University, First Hospital of China Medical University | Liver Cirrhosis, Portal Hypertension, Gastroesophageal Varices | 04/23 | 01/25 | | |
NCT06134973: A Prospective Study on the Application of Liquid Biopsy in the Surveillance of High-risk Population of HCC. |
|
|
| Recruiting | N/A | 1000 | RoW | ultrasonic testing | Tianjin Third Central Hospital, BGI, China | Hepatocellular Carcinoma | 06/25 | 06/25 | | |
NCT04546360: Spleen Stiffness Combined With Liver Stiffness Measured by 2D-SWE for the Screening of High-risk Varices in Compensated Advanced Chronic Liver Disease (CHESS2004) |
|
|
| Completed | N/A | 381 | RoW | Esophagogasrtoduodendoscopy, spleen stiffness measurement and liver stiffness measurement. | Hepatopancreatobiliary Surgery Institute of Gansu Province, LanZhou University, Tianjin Second People's Hospital, The Sixth People's Hospital of Shenyang, Hospital of the Chengdu Office of the People's Government of Tibet Autonomous Region, The Central Hospital of Lishui City, Guangxi Zhuang Autonomous Region | Compensated Advanced Chronic Liver Disease, Variceal Hemorrhage | 12/22 | 12/22 | | |
NCT05626985: Refinement and Validation of a Diagnostic Model (GAMAD) for Early Detection of Hepatocellular Carcinoma |
|
|
| Recruiting | N/A | 2000 | RoW | GAMAD | Singlera Genomics Inc., The First Hospital of Jilin University | Hepatocellular Carcinoma | 10/24 | 12/24 | | |
